Impact of dronedarone in atrial fibrillation and flutter on stroke reduction

Clinical Interventions in Aging

Volumn 5, Issue 1, 2010, Pages 63-69

  Christiansen, Christine Benn ^a   Torp Pedersen, Christian ^a   Kober, Lars ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Atrial fibrillation; Dronedarone; Stroke

Indexed keywords

AMIODARONE; DRONEDARONE; PLACEBO; SOTALOL;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HEART RATE; HOSPITAL ADMISSION; HUMAN; KIDNEY FUNCTION; LIVER DISEASE; LUNG DISEASE; MORTALITY; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SIDE EFFECT; SINUS RHYTHM; SKIN DISCOLORATION; STROKE; THROMBOSIS; THYROID DISEASE; UNSTABLE ANGINA PECTORIS;

EID: 77951162467     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/cia.s8883     Document Type: Review

References (18)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269-1276.
2. Bonita R. Epidemiology of stroke. Lancet. 1992;339:342-344.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
4. Sherman DG, Kim SG, Boop BS, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med. 2005;165:1185-1191.
5. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005;165:258-262.
6. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84:527-539.
7. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-1511.
8. Gautier P, Guillemare E, Marion A, Bertrand JP, Tourneur Y, Nisato D. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol. 2003;41:191-202.
9. Chatelain P, Meysmans L, Matteazzi JR, Beaufort P, Clinet M. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol. 1995;116:1949-1956.
10. + current in guinea pig atrial cells. J Cardiovasc Pharmacol. 2000;36:802-805.
11. Zimetbaum PJ. Dronedarone for atrial fibrillation an odyssey. N Engl J Med. 2009;360:1811-1813.
12. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481-1487.
13. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.
14. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156:527:e521-e529.
15. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54:1089-1095.
16. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687.
17. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64: 785-791.
18. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174-1180.